Abbott Laboratories: Buy The Dip On This Dividend King

Abbott Laboratories presents a compelling buy-the-dip opportunity, as short-term headwinds and conservative guidance overshadow its durable, diversified growth platform. ABT's diversified healthcare platform is reshaping toward higher-growth areas, highlighted by the Exact Sciences acquisition, expected to add $3B in sales this year. Medical devices and pharmaceuticals segments continue to deliver above-market growth, while the dividend remains well-covered, with a 2.6% yield and 8.5% 5-year CAGR.